J Korean Soc Transplant.  2019 Mar;33(1):6-12. 10.4285/jkstn.2019.33.1.6.

Angiotensin II type 1 receptor antibodies in kidney transplantation

Affiliations
  • 1Department of Laboratory Medicine, International St. Mary's Hospital, College of Medicine, Catholic Kwandong University, Incheon, Korea.
  • 2Department of Laboratory Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. ejoh@catholic.ac.kr

Abstract

Angiotensin II type 1 receptor (AT1R) antibodies directly injure endothelial and vascular smooth muscle cells by activating transcription factors associated with proinflammatory responses. Previous studies have shown that AT1R antibodies are associated with allograft rejection and decreased graft survival in kidney transplantation. Development of enzyme-linked immunosorbent assay has facilitated semiquantitative detection of AT1R antibodies. Assessing AT1R antibodies along with donor specific human leukocyte antigen antibodies may have potential to identify patients with possible risk for allograft injury and improve overall outcomes. In this review, we summarize recent clinical studies about AT1R antibodies in kidney transplantation and provide perspectives for future research area.

Keyword

Transplantation; Receptor; Angiotensin, type 1; Kidney

MeSH Terms

Activating Transcription Factors
Allografts
Angiotensin II*
Angiotensins*
Antibodies
Enzyme-Linked Immunosorbent Assay
Graft Survival
Humans
Kidney Transplantation*
Kidney*
Leukocytes
Muscle, Smooth, Vascular
Receptor, Angiotensin, Type 1*
Tissue Donors
Transplantation
Activating Transcription Factors
Angiotensin II
Angiotensins
Antibodies
Receptor, Angiotensin, Type 1

Reference

1. Michielsen LA, van Zuilen AD, Krebber MM, Verhaar MC, Otten HG. Clinical value of non-HLA antibodies in kidney transplantation: still an enigma? Transplant Rev (Orlando). 2016; 30:195–202.
Article
2. Zhang Q, Reed EF. The importance of non-HLA antibodies in transplantation. Nat Rev Nephrol. 2016; 12:484–495.
Article
3. Oh EJ, Park H, Park KU, Kang ES, Kim HS, Song EY. Interlaboratory comparison of the results of lifecodes LSA class I and class II single antigen kits for human leukocyte antigen antibody detection. Ann Lab Med. 2015; 35:321–328.
Article
4. Loupy A, Lefaucheur C, Vernerey D, Prugger C, Duong van, Mooney N, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med. 2013; 369:1215–1226.
Article
5. Racusen LC, Haas M. Antibody-mediated rejection in renal allografts: lessons from pathology. Clin J Am Soc Nephrol. 2006; 1:415–420.
Article
6. Colvin RB. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol. 2007; 18:1046–1056.
Article
7. Opelz G. Collaborative Transplant Study. Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet. 2005; 365:1570–1576.
Article
8. Dragun D, Müller DN, Bräsen JH, Fritsche L, Nieminen-Kelhä M, Dechend R, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med. 2005; 352:558–569.
Article
9. Reinsmoen NL, Lai CH, Heidecke H, Haas M, Cao K, OngG , et al. Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients. Transplantation. 2010; 90:1473–1477.
Article
10. Giral M, Foucher Y, Dufay A, Van Huyen JP, Renaudin K, Moreau A, et al. Pretransplant sensitization against angiotensin II type 1 receptor is a risk factor for acute rejection and graft loss. Am J Transplant. 2013; 13:2567–2576.
Article
11. Taniguchi M, Rebellato LM, Cai J, Hopfield J, Briley KP, Haisch CE, et al. Higher risk of kidney graft failure in the presence of anti-angiotensin II type-1 receptor antibodies. Am J Transplant. 2013; 13:2577–2589.
Article
12. Lee J, Huh KH, Park Y, Park BG, Yang J, Jeong JC, et al. The clinicopathological relevance of pretransplant anti-angiotensin II type 1 receptor antibodies in renal transplantation. Nephrol Dial Transplant. 2017; 32:1244–1250.
Article
13. Pearl MH, Zhang Q, Palma Diaz MF, Grotts J, Rossetti M, Elashoff D, et al. Angiotensin II type 1 receptor antibodies are associated with inflammatory cytokines and poor clinical outcomes in pediatric kidney transplantation. Kidney Int. 2018; 93:260–269.
Article
14. Min JW, Lee H, Choi BS, Park CW, Yang CW, Kim YS, et al. Clinical impact of pre-transplant antibodies against angiotensin II type I receptor and major histocompatibility complex class I-related chain A in kidney transplant patients. Ann Lab Med. 2018; 38:450–457.
Article
15. Sevá Pessôa B, van der Lubbe N, Verdonk K, Roks AJ, Hoorn EJ, Danser AH. Key developments in renin-angiotensinaldosterone system inhibition. Nat Rev Nephrol. 2013; 9:26–36.
Article
16. Dragun D, Catar R, Kusch A, Heidecke H, Philippe A. Non-HLA-antibodies targeting angiotensin type 1 receptor and antibody mediated rejection. Hum Immunol. 2012; 73:1282–1286.
Article
17. Elton TS, Martin MM. Alternative splicing: a novel mechanism to fine-tune the expression and function of the human AT1 receptor. Trends Endocrinol Metab. 2003; 14:66–71.
Article
18. Miller JA, Scholey JW. The impact of renin-angiotensin system polymorphisms on physiological and pathophysiological processes in humans. Curr Opin Nephrol Hypertens. 2004; 13:101–106.
Article
19. Rüster C, Wolf G. Angiotensin II as a morphogenic cytokine stimulating renal fibrogenesis. J Am Soc Nephrol. 2011; 22:1189–1199.
Article
20. Yamada C, Huang Y, Norman S, Naik A, Moussa O, Samaniego M, et al. Efficacy of therapeutic plasma exchange on angiotensin II type-1 receptor antibodies on two kidney transplant recipients. J Clin Apher. 2018; 33:673–677.
Article
21. Dzau VJ. Theodore cooper lecture: tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension. 2001; 37:1047–1052.
Article
22. Cresci B, Giannini S, Pala L, Mavilia C, Manuelli C, Cappugi P, et al. AT1 and AT2 receptors in human glomerular endothelial cells at different passages. Microvasc Res. 2003; 66:22–29.
Article
23. Wallukat G, Homuth V, Fischer T, Lindschau C, Horstkamp B, Jüpner A, et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest. 1999; 103:945–952.
Article
24. Dragun D, Catar R, Philippe A. Non-HLA antibodies in solid organ transplantation: recent concepts and clinical relevance. Curr Opin Organ Transplant. 2013; 18:430–435.
25. Reinsmoen NL. Role of angiotensin II type 1 receptoractivating antibodies in solid organ transplantation. Hum Immunol. 2013; 74:1474–1477.
Article
26. Dragun D. The role of angiotensin II type 1 receptor-activating antibodies in renal allograft vascular rejection. Pediatr Nephrol. 2007; 22:911–914.
Article
27. Philogene MC, Bagnasco S, Kraus ES, Montgomery RA, Dragun D, Leffell MS, et al. Anti-angiotensin II type 1 receptor and anti-endothelial cell antibodies: a cross-sectional analysis of pathological findings in allograft biopsies. Transplantation. 2017; 101:608–615.
28. Fichtner A, Süsal C, Schröder C, Höcker B, Rieger S, Waldherr R, et al. Association of angiotensin II type 1 receptor antibodies with graft histology, function and survival in paediatric renal transplant recipients. Nephrol Dial Transplant. 2018; 33:1065–1072.
Article
29. Banasik M, Boratyńska M, Kościelska-Kasprzak K, Kamińska D, Bartoszek D, Zabińska M, et al. The influence of non-HLA antibodies directed against angiotensin II type 1 receptor (AT1R) on early renal transplant outcomes. Transpl Int. 2014; 27:1029–1038.
Article
30. Lee H, Kim JI, Moon IS, Chung BH, Yang CW, Kim Y, et al. Investigation of serum angiotensin II type 1 receptor antibodies at the time of renal allograft rejection. Ann Lab Med. 2015; 35:314–320.
Article
31. Fuss A, Hope CM, Deayton S, Bennett GD, Holdsworth R, Carroll RP, et al. C4d-negative antibody-mediated rejection with high anti-angiotensin II type I receptor antibodies in absence of donor-specific antibodies. Nephrology (Carlton). 2015; 20:467–473.
Article
32. Philogene MC, Zhou S, Lonze BE, Bagnasco S, Alasfar S, Montgomery RA, et al. Pre-transplant screening for non-HLA antibodies: who should be tested? Hum Immunol. 2018; 79:195–202.
Article
33. Gareau AJ, Wiebe C, Pochinco D, Gibson IW, Ho J, Rush DN, et al. Pre-transplant AT(1)R antibodies correlate with early allograft rejection. Transpl Immunol. 2018; 46:29–35.
34. Cuevas E, Arreola-Guerra JM, Hernández-Méndez EA, Salcedo I, Castelán N, Uribe-Uribe NO, et al. Pretransplant angiotensin II type 1-receptor antibodies are a risk factor for earlier detection of de novo HLA donor-specific antibodies. Nephrol Dial Transplant. 2016; 31:1738–1745.
Article
35. Deltombe C, Gillaizeau F, Anglicheau D, Morelon E, Trébern-Launay K, Le Borgne F, et al. Is pre-transplant sensitization against angiotensin II type 1 receptor still a risk factor of graft and patient outcome in kidney transplantation in the anti-HLA Luminex era? A retrospective study. Transpl Int. 2017; 30:1150–1160.
Article
36. Lee J, Park Y, Kim BS, Lee JG, Kim HJ, Kim YS, et al. Clinical implications of angiotensin II type 1 receptor antibodies in antibody-mediated rejection without detectable donor-specific HLA antibodies after renal transplantation. Transplant Proc. 2015; 47:649–652.
Article
37. Lim MA, Palmer M, Trofe-Clark J, Bloom RD, Jackson A, Philogene MC, et al. Histopathologic changes in anti-angiotensin II type 1 receptor antibody-positive kidney transplant recipients with acute rejection and no donor specific HLA antibodies. Hum Immunol. 2017; 78:350–356.
Article
38. Pinelli DF, Friedewald JJ, Haarberg KM, Radhakrishnan SL, Zitzner JR, Hanshew WE, et al. Assessing the potential of angiotensin II type 1 receptor and donor specific anti-endothelial cell antibodies to predict long-term kidney graft outcome. Hum Immunol. 2017; 78:421–427.
Article
39. Martin L, Guignier F, Mousson C, Rageot D, Justrabo E, Rifle G. Detection of donor-specific anti-HLA antibodies with flow cytometry in eluates and sera from renal transplant recipients with chronic allograft nephropathy. Transplantation. 2003; 76:395–400.
Article
40. Sas A, Donizy P, Kościelska-Kasprzak K, Kamińska D, Mazanowska O, Krajewska M, et al. Histopathological relevance of angiotensin II type 1 receptor in renal transplant biopsy. Transplant Proc. 2018; 50:1847–1849.
Article
41. Jobert A, Rao N, Deayton S, Bennett GD, Brealey J, Nolan J, et al. Angiotensin II type 1 receptor antibody precipitating acute vascular rejection in kidney transplantation. Nephrology (Carlton). 2015; 20:Suppl 1. 10–12.
Article
Full Text Links
  • JKSTN
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr